ZipLine Medical is developing a breakthrough technology platform designed to facilitate noninvasive surgical skin-closure with suture-like outcomes at the speed of staples. As skin closure is common to nearly all surgical procedures, ZipLine’s technology is expected to have application across many medical specialties.

- **UNMET CLINICAL NEEDS.** Skin closure with staples or sutures presents a choice to the surgeon—speed, or good cosmesis. ZipLine has developed a versatile skin-closure platform that offers **both** suture-like outcomes at the speed of staples, via a simple, easy-to-learn and easy-to-use device.

- **LARGE MARKETS.** Over $4 billion existing market opportunity worldwide covering most surgical procedures involving skin incision. Initial target applications: C-section, laparotomy, pacemaker/ICD implant, laparoscopic port, orthopedic, and excisional skin biopsy closure.

- **NO REGULATORY HURDLES.** ZipLine’s initial products are “Class I, Exempt,” with US market launch scheduled for 2Q 2012 and EU launch in 2013.

- **FAVORABLE MEDICAL ECONOMICS.** ZipLine’s products are designed to replace sutures and staples and are, therefore, similarly reimbursed.

- **OUTSTANDING PRECLINICAL RESULTS.** Results were evaluated by a blinded panel of Board-certified plastic surgeons, demonstrating cosmetic-equivalency to subcuticular suture closure and histological evidence of equivalency to suture control.

- **BROAD IP AND PRODUCT PIPELINE.** ZipLine’s platform technology has broad IP coverage, and additional IP has been applied for to cover a robust pipeline of additional products.

- **SIGNIFICANT COMPETITIVE ADVANTAGES.** ZipLine’s platform is designed to facilitate noninvasive surgical skin-closure with closure speeds comparable to staples and cosmetic outcomes comparable to meticulous suture closure.

- ** Experienced, Successful Leadership.** Founder Amir Belson, MD, previously founded NeoGuide Systems, acquired by Intuitive Surgical in 2009; John Tighe was previously President and CEO of PEAK Surgical, acquired by Medtronic in 2011.

- **World-Class Scientific Advisory Board.** ZipLine is advised by Key Opinion Leaders (KOLs) from targeted specialties, including General Surgery, Plastic and Reconstructive Surgery, Dermatological Surgery, Gynecology/Oncology, Ob/Gyn, Orthopedic Surgery, and Spine Surgery.

- **Attractive Exit Opportunities.** There are multiple, well-defined, complementary, logical acquirers of ZipLine’s one-of-a-kind products.

<table>
<thead>
<tr>
<th>PROCEDURES</th>
<th>US</th>
<th>EU</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Surgery</td>
<td>1,278,000</td>
<td>1,278,000</td>
<td>2,556,000</td>
</tr>
<tr>
<td>Orthopaedic</td>
<td>2,046,000</td>
<td>2,046,000</td>
<td>4,092,000</td>
</tr>
<tr>
<td>Electrophysiology</td>
<td>593,300</td>
<td>593,300</td>
<td>1,187,000</td>
</tr>
<tr>
<td>Ob/Gyn</td>
<td>1,873,000</td>
<td>1,873,000</td>
<td>3,746,000</td>
</tr>
<tr>
<td>Skin Excision</td>
<td>1,030,000</td>
<td>1,030,000</td>
<td>2,060,000</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>6,820,000</strong></td>
<td><strong>6,820,000</strong></td>
<td><strong>13,641,000</strong></td>
</tr>
</tbody>
</table>

Source: Medtech Insight Reports 2010

*NOTICE: ZipLine™ devices are classified by the U.S. FDA as ‘Class I, Exempt.’ The Company has confirmation of FDA determination of this classification on file.*

---

**Company Fact Sheet**

**CONTACTS & KEY INFORMATION**

| Headquarters       | 747 Camden Ave., Suite A  
|                   | Campbell, CA 95008  
|                   | 888-326-8999, 408-412-7228  
| Website            | www.ziplinemedical.com  
| Ownership          | Privately held  
| Investors          | Claremont Creek Ventures, X/Seed Capital Management  
| Industry           | Medical technology  
| Sectors            | General Surgery, Electrophysiology, Ob/Gyn, Orthopedics, Dermatology, Emergency Medicine  
| Platform           | PRELOC™: Pre-placement RE-aligning LOW-tension Closure  
| Opportunity        | Over $4 billion worldwide  
| Contact            | Ronald Trahan, APR Ronald Trahan Associates, Inc.  

**LEADERSHIP AND ADVISORS**

John R. Tighe  
President, CEO, ZipLine Medical. Previously, President and CEO of PEAK Surgical, acquired by Medtronic, 2011; prior to PEAK, SVP and GM of all business units for ArthroCare Corp.

Amir Belson, MD  
Founder, CTO of ZipLine Medical; Founder of NeoGuide Systems, acquired by Intuitive Surgical, 2009; also Founder of Emboline, RadGuard Medical, ThermoCure, Vascular Pathways, and VasoStitch.

Fuad Abuabara, MD  
Adjunct Clinical Professor of Dermatology, Stanford; Clinical Instructor, Palo Alto VA

Jonathan Berek, MD  
Chair, Dept. of Ob/Gyn, Stanford; Clinical Instructor, Palo Alto VA

Greg Buncke, MD  
Assistant Clinical Professor of Surgery, Plastic and Reconstructive Surgery, UCSF

Thomas Krummel, MD  
General surgeon; Chair, Dept. of Surgery, Stanford; Co-Director, Stanford Biodesign Program

Leslie Matthews, MD  
Chief, Orthopedic Surgery, Union Memorial Hospital

Charlene Reiminitz, MD  
Fellow, American College of Obstetricians & Gynecologists, and American College of Surgeons

---

**The Market**

The w/w total available wound closure market for ZipLine’s initial target applications is 13.6 billion procedures.

<table>
<thead>
<tr>
<th>PROCEDURES</th>
<th>US</th>
<th>EU</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Surgery</td>
<td>1,278,000</td>
<td>1,278,000</td>
<td>2,556,000</td>
</tr>
<tr>
<td>Orthopaedic</td>
<td>2,046,000</td>
<td>2,046,000</td>
<td>4,092,000</td>
</tr>
<tr>
<td>Electrophysiology</td>
<td>593,300</td>
<td>593,300</td>
<td>1,187,000</td>
</tr>
<tr>
<td>Ob/Gyn</td>
<td>1,873,000</td>
<td>1,873,000</td>
<td>3,746,000</td>
</tr>
<tr>
<td>Skin Excision</td>
<td>1,030,000</td>
<td>1,030,000</td>
<td>2,060,000</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>6,820,000</strong></td>
<td><strong>6,820,000</strong></td>
<td><strong>13,641,000</strong></td>
</tr>
</tbody>
</table>

Source: Medtech Insight Reports 2010